Survival rates for placental-site trophoblastic tumours (PSTTs) vary depending on how long ago the related pregnancy occurred. The study found that patients with stage I disease had a 10-year probability of overall survival of 90%, while those with recurrent disease or disease resistant to treatment had poor survival.
A study published in World Journal of Gastroenterology found that patients with extrahepatic disease, high carcinoembriogenic antigen levels, or multiple nodules have poorer survival rates. Despite this, advances in surgical technique and complementary treatments are increasing the number of patients benefiting from curative treatment.
A Swedish study found that 70% of extremely preterm infants born alive between 22-26 weeks survived at least one year. Proactive perinatal management likely contributed to this outcome, making it crucial to reassess decision-making for these infants.
Researchers at M.D. Anderson Cancer Center found a significant increase in median overall survival from 8 to 30 months for patients with advanced disease, and a projected five-year survival rate of over 30 percent. The study attributes the improvements to better surgical interventions and new chemotherapeutic agents.
Researchers at Fred Hutchinson Cancer Center identified two proteins associated with chronic inflammation linked to long-term survival in breast cancer patients. Elevated levels of C-reactive protein and serum amyloid A are associated with reduced overall survival, regardless of patient age or tumor stage.
Overall median survival improved from 3.5 months in period A to 12 months in period C, despite stage of disease at presentation affecting survival. Surgical resection is the only curative treatment, but many patients present with advanced-stage disease.
A new study from Henry Ford Hospital found that radical prostatectomy significantly increases long-term survival for men under 50 with prostate cancer. The procedure improved cancer-specific and overall survival rates compared to radiotherapy or watchful waiting, making it the recommended treatment option for younger patients.
A study found that patients diagnosed with lung cancer through CT scans had a significantly higher 5-year survival rate (91.2%) compared to those diagnosed with x-rays (77.8%). The study suggests that early detection of the disease using CT scans improves patient prognosis.
The Phase 3 IMPACT trial found that sipuleucel-T significantly prolonged overall survival by 4.1 months and improved three-year survival by 38 percent compared to placebo. This innovative immunotherapy reduced the risk of death by 22.5 percent.
A study of liver transplant patients found that HIV positive individuals have similar survival rates to those who are HIV negative. However, co-infection with hepatitis C virus significantly predicts poorer outcomes in this patient group, emphasizing the need for targeted antiviral therapy.
A new report reveals a significant increase in the number of people diagnosed with cancer in Ireland, but also shows that survival rates are rising for certain types of cancer. The report highlights the importance of prevention and early detection in reducing the burden of cancer.
A recent study published in the Addiction journal found that continued abstinence from alcohol significantly increases survival rates for patients with alcohol-related cirrhosis of the liver. The research, led by Dr Nick Sheron, indicates that drinking status is the most important factor determining long-term survival in these patients.
A new study by researchers at the University of Michigan Comprehensive Cancer Center found that higher doses of radiation combined with chemotherapy improve survival in patients with stage III lung cancer. Concurrent chemotherapy increases treatment effectiveness and overall survival rates.
A new study from the University of Michigan Comprehensive Cancer Center found that health choices at diagnosis play a major role in head and neck cancer survival. Patients with better habits such as not smoking, exercising regularly, eating enough fruits, and limiting alcohol use had longer survival times.
A study published in The Lancet found that whole-body CT scans improved survival rates for patients with severe injuries, with a relative risk reduction of 25% and 13%. The procedure was shown to be an independent predictor of survival.
A new study analyzing UK cancer survival data reveals a modest improvement in survival rates since the introduction of the NHS cancer plan in 2000. However, significant regional variations in survival remain, with affluent southern regions showing better outcomes.
A new study has found that maintenance rituximab therapy improves progression-free survival in patients with stage III-IV indolent lymphoma. The treatment showed significant benefits, including a 22% improvement in disease response and a 68% three-year progression-free survival rate.
The EORTC-NCIC trial found that adding chemotherapy to radiotherapy significantly increases survival in glioblastoma patients, with improved outcomes seen across all clinical prognostic subgroups. The study suggests testing tumour MGMT gene methylation status to identify patients most likely to benefit from this treatment.
Researchers used a six-gene model to stratify patients with castration-resistant prostate cancer, predicting survival and accuracy rates. The study found the model accurate in predicting low-risk patients' survival and high-risk patients' mortality.
High-flux hemodialysis reduces the risk of premature death in patients with CKD by eliminating large toxins. Patients with diabetes showed a significant survival benefit from high-flux dialysis, while benefits were not observed in all patient groups.
A new study published in The Lancet Oncology found that azacitidine significantly improves the survival of patients with high-risk forms of myelodysplastic syndromes (MDS). Patients treated with azacitidine had a median overall survival of 24.5 months, compared to 15 months for those receiving conventional care.
Patients with relapsed follicular lymphoma who continue on maintenance rituximab therapy after chemotherapy have better overall survival than those without treatment. Rituximab maintenance therapy was associated with a 40% improvement in overall survival relative to observation or retreatment.
A new method uses circulating tumour cells to monitor disease status and predict survival in patients with advanced prostate cancer. Changes in CTC number before and after treatment are strongly associated with risk, making it a more predictive biomarker than PSA.
A study found that lack of general treatment failure and distant metastases 3 years after treatment initiation may be surrogate endpoints for long-term survival in early prostate cancer patients. Another study identified netrin-1 as a potential therapeutic target for non-small cell lung cancer.
A new review of randomized controlled trials has found that radiofrequency ablation significantly improves patient survival compared to percutaneous ethanol injection. Radiofrequency treatment offered a greater survival benefit due to improved local tumor response and more predictable tumor ablation.
Researchers have discovered a gene expression signature associated with survival in advanced ovarian cancer. The study identified specific genes and pathways that correlate with overall survival, providing potential targets for therapies and personalized treatment strategies.
The 'chain of survival' improved out-of-hospital cardiac arrest survival rates in Japan by increasing bystander CPR, early defibrillator use, and advanced life support. The study found a significant decrease in delay times and an increase in neurologically intact survivors.
A study examines racial disparities in survival among black patients diagnosed with early-stage lung cancer. Despite recommended treatment, black patients have lower five-year survival rates compared to white patients.
A Johns Hopkins study found that HIV-positive kidney transplant recipients can achieve one-year survival rates comparable to those without HIV, provided key risk factors for transplant failure are recognized and controlled. The study's results reflect the impact of newer antiretroviral therapies on reducing HIV-related deaths.
Researchers found that obese and non-obese patients have the same overall survival rate for ovarian cancer if their chemotherapy doses are tailored to their individual body weight. The study, published in Gynecologic Oncology, challenges earlier research suggesting obesity reduces ovarian cancer survival rates.
A study by the University of Texas M. D. Anderson Cancer Center found that women with high levels of Dicer and Drosha proteins had a median survival of 11 years, while those with low levels had only 2.66 years. Low levels of Dicer are also predictive of poor outcomes in lung and breast cancer patients.
A landmark analysis found that continuous treatment with Revlimid and dexamethasone improved overall survival and time to disease progression in multiple myeloma patients. Patients who continued therapy had significantly longer overall survival rates compared to those who discontinued treatment after 10 months or less.
A subanalysis of the AZA-001 phase III trial reveals Vidaza extends overall survival and reduces death risk in elderly higher-risk MDS patients. The treatment also improves one-year survival rates in all response categories.
A subset analysis of the AZA-001 trial demonstrated that Vidaza significantly improved overall survival in patients with WHO-defined acute myeloid leukemia (AML) compared to conventional care regimens. The study also showed reduced infections, hospitalizations, and red blood cell transfusions.
A randomized trial found that systematic pelvic lymphadenectomy did not improve disease-free or overall survival in women with stage I endometrial cancer. Lymphadenectomy was associated with improved surgical staging and detection of disease spread to pelvic lymph nodes, but no therapeutic benefit.
Head and neck cancer patients with comorbidities have a significantly higher risk of death, with some cases increasing by up to seven-fold. The study highlights the importance of considering co-existing conditions in estimating cancer survival statistics.
A recent study found that individuals with lower socioeconomic status are more likely to be diagnosed with late-stage colorectal cancer, leading to poorer survival rates. The research highlights the importance of removing barriers to healthcare services, including screening tests and treatment for colorectal cancer.
A phase III clinical trial found that adding bevacizumab to erlotinib therapy improves progression-free survival in advanced non-small cell lung cancer patients, but not overall survival. The combination also shows a response rate and tumor shrinkage.
A recent study published by the American Society for Radiation Oncology found that males diagnosed with non-small cell lung cancer have a higher mortality rate than females. The research also revealed that gender is a significant prognostic factor in lung cancer patients' overall survival rates.
A multi-center phase II clinical trial found improved survival in patients with advanced non-small cell lung cancer treated with chemotherapy and targeted therapies bevacizumab and cetuximab. The combination showed no safety concerns, indicating a potential future treatment option for lung cancer.
A study compared the survival of dialysis patients undergoing heart bypass surgery or stent placement, finding that stents offer best one-year survival but bypass surgery is superior for long-term results. The study's findings suggest that treatment choices depend on individual patient goals and risk tolerance.
A study by Stanford Cancer Center found that younger patients (15-39 years) with lung cancer exhibit better survival rates and distinct clinical features compared to older patients. The age-adjusted incidence rate of lung cancer in younger patients was significantly lower, and they had a higher proportion of distant disease at diagnosis.
A new study challenged conventional notions about salmon survival, finding that juvenile salmon in two west coast rivers had similar survival rates despite the presence of extensive dam networks. The study used tagging and tracking technologies to track small juvenile Pacific salmon from freshwater to ocean destinations.
A recent study found that some endangered Pacific salmon stocks are surviving as well as or better in rivers with hydroelectric dams as in those without. Researchers used acoustic telemetry technology to track juvenile salmon migration and survival rates in the Fraser and Columbia Rivers, revealing a surprising similarity between damme...
A new biologic therapy called TNFeradeTM improved the median survival of patients with locally advanced esophageal cancer from 9.7 to 48.4 months. Researchers found that most tumors were adenocarcinomas and could be treated with surgery after combination therapy, showing promise for this treatment approach.
A new analysis found that African Americans and those from low-income communities have poorer survival rates for head and neck cancer, with earlier diagnosis crucial to improving outcomes. The study reveals racial disparities and socio-economic inequities in cancer treatment, highlighting the need for targeted interventions.
A study of 236 advanced gastric cancer patients found that the metastatic lymph node ratio is significantly correlated with five-year survival rates and can be used to project survival rates. The MLR also reflects the extent and efficiency of lymphadenectomy.
A study found that community-based use of treatment for US gastroesophageal adenocarcinoma varies depending on clinical and non-clinical factors. Chemotherapy and chemoradiation are associated with improved survival rates, while anatomic site differentiation is crucial for effective treatment.
A new model predicts long-term survival of critically ill patients based on seven commonly collected clinical variables. Age and co-morbidity have a significant impact on survival rates, with age being the most critical factor.
Recent research has shown a significant improvement in two-year survival rates for patients with multiple myeloma, from 48-66% in the 1980s to around 90% today. Potent new drugs have been instrumental in this breakthrough, offering improved outcomes without severe side effects.
Advances in treatment have led to increased long-term survival for US children diagnosed with acute lymphoblastic leukemia, acute non-lymphoblastic leukemia, or non-Hodgkin lymphoma. Period analysis reveals improved survival rates between 1990 and 2004, with projections suggesting continued progress through molecularly targeted therapies.
A study of quarter of a million patients found epidural anaesthesia to be safe for intermediate to high-risk surgery, but only slightly improving survival rates. The procedure offers better postoperative pain relief and reduces surgical stress response.
The report found that paediatric-oncology care varied substantially between countries, with access to care or management extremely poor in seven out of ten nations. The five-year survival rate was as low as 5% in some countries, while higher rates were observed in those with greater health expenditure and infrastructure.
A study found that patients receiving kidney transplants who took statin drugs had better survival rates compared to those who did not. Statin therapy was associated with a 36% lower risk of death in renal transplant recipients.
A worldwide study found significant differences in cancer survival rates between rich and poor countries, as well as between black and white men and women in the US. Cancer survival varies widely across regions, with some countries having much higher or lower survival rates than others.
A comprehensive study of 31 countries found significant variations in cancer survival rates, with the US and Europe experiencing lower survival rates compared to other regions. The study reveals a racial gap in cancer survival between black and white populations in the US, with blacks facing a 7-14% lower survival rate.
The addition of hormone therapy following vaccine treatment improved overall survival in patients with castration-resistant prostate cancer. Vaccines can be safely and effectively combined with other therapies, including hormones.
For elderly men with localized prostate cancer, androgen deprivation therapy does not improve survival rates compared to conservative management. The study found lower 10-year prostate cancer-specific survival rates among those using PADT.
A recent study published in The Lancet found that extracorporeal life support (ELS) combined with conventional CPR significantly improves survival rates in adult hospital patients who experience cardiac arrest. ELS enhances coronary blood flow and keeps heart tissue alive, leading to better 30-day and 1-year survival outcomes.
A new vitespen vaccine was tested on post-operative kidney cancer patients, but showed no significant improvement in recurrence-free survival. In early stage disease, patients receiving the vaccine had a lower risk of recurrence, but this finding requires further validation.